Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Sensitization of melanoma cells to alkylating agent-induced DNA damage and cell death via orchestrating oxidative stress and IKKβ inhibition.

Redox biology·2017

Same author

Synergistic Effects of Tetrandrine with Posaconazole Against Aspergillus fumigatus.

Microbial drug resistance (Larchmont, N.Y.)·2017

Same author

A novel NHS mutation causes Nance-Horan Syndrome in a Chinese family.

BMC medical genetics·2017

Same author

Positively charged polypeptide nanogel enhances mucoadhesion and penetrability of 10-hydroxycamptothecin in orthotopic bladder carcinoma.

Journal of controlled release : official journal of the Controlled Release Society·2017

Same author

Methods used to study the oligomeric structure of G-protein-coupled receptors.

Bioscience reports·2017

Same author

Patterns of Early Rejection in Renal Retransplantation: A Single-Center Experience.

Journal of immunology research·2017

Search research articles

Related Experiment Video

Updated: May 17, 2026

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

Bmi1 knockdown inhibits hepatocarcinogenesis.

Zhi-Ping Ruan¹, Rui Xu, Yi Lv

¹Department of Oncology, Medical College of Xi'an Jiaotong University, Xi'an, Shaanxi, People's Republic of China.

International Journal of Oncology

|November 10, 2012

Summary

Bmi1 oncogene promotes liver cancer (hepatocellular carcinoma) by driving cell proliferation and tumor growth. Downregulating Bmi1 inhibits cancer progression and enhances sensitivity to sorafenib, suggesting Bmi1 as a therapeutic target.

More Related Videos

In Vitro Cultivation Techniques for Modeling Liver Organogenesis, Building Assembloids, and Designing Synthetic Tissues using Human Cell Lines

In Vitro Cultivation Techniques for Modeling Liver Organogenesis, Building Assembloids, and Designing Synthetic Tissues using Human Cell Lines

Published on: April 18, 2025

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

Related Experiment Videos

Last Updated: May 17, 2026

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

In Vitro Cultivation Techniques for Modeling Liver Organogenesis, Building Assembloids, and Designing Synthetic Tissues using Human Cell Lines

In Vitro Cultivation Techniques for Modeling Liver Organogenesis, Building Assembloids, and Designing Synthetic Tissues using Human Cell Lines

Published on: April 18, 2025

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

Area of Science:

Oncology
Molecular Biology
Hepatology

Background:

Bmi1 is a known oncogene, but its specific role in liver cancer (hepatocellular carcinoma, HCC) is not fully understood.
Bmi1 represents a potential therapeutic target for HCC treatment.

Purpose of the Study:

To investigate the expression and function of Bmi1 in hepatocarcinogenesis.
To evaluate the therapeutic potential of targeting Bmi1 in HCC.

Main Methods:

Immunohistochemistry and western blot analysis to assess Bmi1 expression in HCC tissues.
shRNA-mediated knockdown of Bmi1 to study its effects in vitro and in vivo.
Flow cytometry for cell cycle analysis.

Main Results:

Bmi1 expression is significantly elevated in HCC tissues compared to normal liver tissues.
Bmi1 downregulation inhibited HCC cell growth, tumorsphere formation, and tumorigenicity in vivo.
Bmi1 knockdown caused cell cycle arrest at the G0/G1 to S phase transition.
Reduced Bmi1 levels enhanced HCC sensitivity to sorafenib.

Conclusions:

Bmi1 acts as a promoter of cell proliferation and hepatocarcinogenesis.
Targeting Bmi1 could be a viable therapeutic strategy for hepatocellular carcinoma.